PMID- 19325010
OWN - NLM
STAT- MEDLINE
DCOM- 20090611
LR  - 20191210
IS  - 1530-8561 (Electronic)
IS  - 0009-9147 (Linking)
VI  - 55
IP  - 5
DP  - 2009 May
TI  - New dual monoclonal ELISA for measuring plasma osteopontin as a biomarker 
      associated with survival in prostate cancer: clinical validation and comparison 
      of multiple ELISAs.
PG  - 895-903
LID - 10.1373/clinchem.2008.117465 [doi]
AB  - BACKGROUND: A previously developed monoclonal/polyclonal ELISA (Mono/Poly) to 
      detect plasma concentrations of osteopontin (OPN) was shown to provide prognostic 
      information in breast, prostate, and other cancers. Here we describe the clinical 
      validation of a new dual monoclonal (Dual Mono) assay. We compared both assays 
      with 4 assays that recognize defined regions of OPN protein (dual polyclonal 
      systems 5-1, 4-1, 4-3 and polyclonal-monoclonal system 1-3). METHODS: OPN 
      sequences recognized by the monoclonal antibodies that make up the Dual Mono 
      ELISA were identified by Pepscan CLIPS analysis. Using the 6 ELISAs, we measured 
      OPN in plasma from 66 patients with castration-resistant prostate cancer, and we 
      assessed the ability of each assay to predict patient survival. RESULTS: The 
      assays varied in measured plasma OPN concentrations, with median values ranging 
      from 112 to 1740 mug/L, and ability to predict patient survival. By Cox 
      univariable regression of survival by tertiles of OPN, the Mono/Poly and Dual 
      Mono ELISAs had the highest log-rank chi(2) values. After adjustment for risk 
      factors independently associated with survival in our samples, OPN remained 
      associated with survival only for the Mono/Poly and Dual Mono systems. 
      CONCLUSIONS: OPN plasma values varied significantly depending on the assay used. 
      Only the Mono/Poly and Dual Mono systems were independently associated with 
      survival in a population of men with castration-resistant prostate cancer. The 
      availability of a clinically validated, dual monoclonal-based ELISA will provide 
      consistent reagents for studies of OPN plasma concentrations in cancer and other 
      pathologies.
FAU - Anborgh, Pieter H
AU  - Anborgh PH
AD  - London Regional Cancer Program, London, Ontario, Canada.
FAU - Wilson, Sylvia M
AU  - Wilson SM
FAU - Tuck, Alan B
AU  - Tuck AB
FAU - Winquist, Eric
AU  - Winquist E
FAU - Schmidt, Nancy
AU  - Schmidt N
FAU - Hart, Russell
AU  - Hart R
FAU - Kon, Shigeyuki
AU  - Kon S
FAU - Maeda, Masahiro
AU  - Maeda M
FAU - Uede, Toshimitsu
AU  - Uede T
FAU - Stitt, Larry W
AU  - Stitt LW
FAU - Chambers, Ann F
AU  - Chambers AF
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Validation Study
DEP - 20090326
PL  - England
TA  - Clin Chem
JT  - Clinical chemistry
JID - 9421549
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Peptide Fragments)
RN  - 106441-73-0 (Osteopontin)
SB  - IM
CIN - Clin Chem. 2009 May;55(5):848-9. PMID: 19299538
MH  - Animals
MH  - Antibodies, Monoclonal/*chemistry
MH  - Biomarkers, Tumor/*blood
MH  - Enzyme-Linked Immunosorbent Assay/*methods
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Neoplasms, Hormone-Dependent/blood
MH  - Osteopontin/*blood
MH  - Peptide Fragments/blood
MH  - Predictive Value of Tests
MH  - Proportional Hazards Models
MH  - Prostatic Neoplasms/*blood
EDAT- 2009/03/28 09:00
MHDA- 2009/06/12 09:00
CRDT- 2009/03/28 09:00
PHST- 2009/03/28 09:00 [entrez]
PHST- 2009/03/28 09:00 [pubmed]
PHST- 2009/06/12 09:00 [medline]
AID - clinchem.2008.117465 [pii]
AID - 10.1373/clinchem.2008.117465 [doi]
PST - ppublish
SO  - Clin Chem. 2009 May;55(5):895-903. doi: 10.1373/clinchem.2008.117465. Epub 2009 
      Mar 26.